AI assistant
IMMUNIC, INC. — Director's Dealing 2019
Jan 14, 2019
10196_dirs_2019-01-14_7fbdb40c-5a15-46da-adcb-ca0abe3f91f4.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: VITAL THERAPIES INC (VTL)
CIK: 0001280776
Period of Report: 2019-01-11
Reporting Person: Ashley Robert A. (Chief Scientific Officer, EVP)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2019-01-11 | Stock Option (right to buy) | $0.4284 | D | 93377 | Disposed | 2022-03-31 | Common Stock (93377.0) | Direct |
| 2019-01-11 | Stock Option (right to buy) | $0.4284 | D | 23344 | Disposed | 2022-04-24 | Common Stock (23344.0) | Direct |
| 2019-01-11 | Stock Option (right to buy) | $8.0 | D | 241670 | Disposed | 2022-09-25 | Common Stock (241670.0) | Direct |
| 2019-01-11 | Stock Option (right to buy) | $8.28 | D | 75000 | Disposed | 2026-05-12 | Common Stock (75000.0) | Direct |
| 2019-01-11 | Stock Option (right to buy) | $3.2 | D | 75000 | Disposed | 2027-06-09 | Common Stock (75000.0) | Direct |
| 2019-01-11 | Stock Option (right to buy) | $5.0 | D | 75000 | Disposed | 2028-06-08 | Common Stock (75000.0) | Direct |
| 2019-01-11 | Restricted Stock Units | $ | A | 816634 | Acquired | Common Stock (816634.0) | Direct |
Footnotes
F1: The option was cancelled by mutual agreement of the reporting person and Vital Therapies, Inc. The reporting person received a restricted stock unit award as reported in this Form 4 as consideration for this cancellation.
F2: Subject to the reporting person continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan (the "Plan")), one forty-eighth (1/48th) of the shares subject to the option vested and became exercisable one month after the vesting commencement date of April 16, 2016, and an additional one forty-eighth (1/48th) of the shares vest and become exercisable at the end of each monthly period thereafter. One hundred percent (100%) of the unvested portion of the option, if any, shall vest in the event of a termination without cause following a Change in Control (as defined in the Plan).
F3: Subject to the reporting person continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan (the "Plan")), one forty-eighth (1/48th) of the shares subject to the option vested and became exercisable one month after the vesting commencement date of June 10, 2017, and an additional one forty-eighth (1/48th) of the shares vest and become exercisable at the end of each monthly period thereafter. One hundred percent (100%) of the unvested portion of the option, if any, shall vest in the event of a termination without cause following a Change in Control (as defined in the Plan).
F4: Subject to the reporting person continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan (the "Plan")), one forty-eighth (1/48th) of the shares subject to the option vested and became exercisable one month after the vesting commencement date of June 9, 2018, and an additional one forty-eighth (1/48th) of the shares vest and become exercisable at the end of each monthly period thereafter. One hundred percent (100%) of the unvested portion of the option, if any, shall vest in the event of a termination without cause following a Change in Control (as defined in the Plan).
F5: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Vital Therapies, Inc. Common Stock.
F6: Subject to the reporting person continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan), twenty five percent (25%) of the RSUs vest annually after the vesting commencement date of January 11, 2019. One hundred percent (100%) of the unvested portion of the RSUs, if any, shall vest in the event of a Termination without Cause or Resignation for Good Reason (each as defined in the reporting person's Change of Control and Severance Agreement).